Valneva SE (NASDAQ:VALN - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $6.73, but opened at $7.06. Valneva shares last traded at $7.15, with a volume of 6,867 shares trading hands.
Analyst Ratings Changes
A number of research analysts have weighed in on VALN shares. Guggenheim decreased their price objective on Valneva from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Monday. HC Wainwright reissued a "buy" rating and issued a $17.00 price target on shares of Valneva in a research note on Friday.
View Our Latest Analysis on VALN
Valneva Stock Up 7.4 %
The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $625.71 million, a PE ratio of -59.23 and a beta of 1.93. The business has a 50-day moving average price of $6.34 and a 200-day moving average price of $5.58.
Valneva (NASDAQ:VALN - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The company had revenue of $56.48 million during the quarter, compared to analysts' expectations of $55.64 million. Equities research analysts forecast that Valneva SE will post 0.13 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Valneva
An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new position in shares of Valneva SE (NASDAQ:VALN - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,244 shares of the company's stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
